Combination therapy shows promising results in newly diagnosed multiple myeloma patients
An overall response of 100% with isatuximab plus carfilzomib, lenalidomide and dexamethasone and a progression free survival rate for the first 50 patients of 79.6% and 75.5% after 12 and 24 months are good news for patients with newly diagnosed multiple myeloma.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in